Cargando…

Controlling the SARS-CoV-2 spike glycoprotein conformation

The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Henderson, Rory, Edwards, Robert J., Mansouri, Katayoun, Janowska, Katarzyna, Stalls, Victoria, Gobeil, Sophie, Kopp, Megan, Li, Dapeng, Parks, Rob, Hsu, Allen L., Borgnia, Mario J., Haynes, Barton F., Acharya, Priyamvada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581954/
https://www.ncbi.nlm.nih.gov/pubmed/32699321
http://dx.doi.org/10.1038/s41594-020-0479-4
_version_ 1784596885775843328
author Henderson, Rory
Edwards, Robert J.
Mansouri, Katayoun
Janowska, Katarzyna
Stalls, Victoria
Gobeil, Sophie
Kopp, Megan
Li, Dapeng
Parks, Rob
Hsu, Allen L.
Borgnia, Mario J.
Haynes, Barton F.
Acharya, Priyamvada
author_facet Henderson, Rory
Edwards, Robert J.
Mansouri, Katayoun
Janowska, Katarzyna
Stalls, Victoria
Gobeil, Sophie
Kopp, Megan
Li, Dapeng
Parks, Rob
Hsu, Allen L.
Borgnia, Mario J.
Haynes, Barton F.
Acharya, Priyamvada
author_sort Henderson, Rory
collection PubMed
description The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available β-CoV S-protein structures. Despite overall similarity in domain organization, we found that S-proteins from different β-CoV display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for SARS-CoV-2 S-protein in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs ‘down’ position or adopts ‘up’ state conformations more readily than wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and provide a framework for the development of engineered coronavirus spike proteins for vaccine applications.
format Online
Article
Text
id pubmed-8581954
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-85819542021-11-11 Controlling the SARS-CoV-2 spike glycoprotein conformation Henderson, Rory Edwards, Robert J. Mansouri, Katayoun Janowska, Katarzyna Stalls, Victoria Gobeil, Sophie Kopp, Megan Li, Dapeng Parks, Rob Hsu, Allen L. Borgnia, Mario J. Haynes, Barton F. Acharya, Priyamvada Nat Struct Mol Biol Article The coronavirus (CoV) spike (S) protein, involved in viral–host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available β-CoV S-protein structures. Despite overall similarity in domain organization, we found that S-proteins from different β-CoV display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for SARS-CoV-2 S-protein in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs ‘down’ position or adopts ‘up’ state conformations more readily than wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and provide a framework for the development of engineered coronavirus spike proteins for vaccine applications. 2020-07-22 2020-10 /pmc/articles/PMC8581954/ /pubmed/32699321 http://dx.doi.org/10.1038/s41594-020-0479-4 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Henderson, Rory
Edwards, Robert J.
Mansouri, Katayoun
Janowska, Katarzyna
Stalls, Victoria
Gobeil, Sophie
Kopp, Megan
Li, Dapeng
Parks, Rob
Hsu, Allen L.
Borgnia, Mario J.
Haynes, Barton F.
Acharya, Priyamvada
Controlling the SARS-CoV-2 spike glycoprotein conformation
title Controlling the SARS-CoV-2 spike glycoprotein conformation
title_full Controlling the SARS-CoV-2 spike glycoprotein conformation
title_fullStr Controlling the SARS-CoV-2 spike glycoprotein conformation
title_full_unstemmed Controlling the SARS-CoV-2 spike glycoprotein conformation
title_short Controlling the SARS-CoV-2 spike glycoprotein conformation
title_sort controlling the sars-cov-2 spike glycoprotein conformation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581954/
https://www.ncbi.nlm.nih.gov/pubmed/32699321
http://dx.doi.org/10.1038/s41594-020-0479-4
work_keys_str_mv AT hendersonrory controllingthesarscov2spikeglycoproteinconformation
AT edwardsrobertj controllingthesarscov2spikeglycoproteinconformation
AT mansourikatayoun controllingthesarscov2spikeglycoproteinconformation
AT janowskakatarzyna controllingthesarscov2spikeglycoproteinconformation
AT stallsvictoria controllingthesarscov2spikeglycoproteinconformation
AT gobeilsophie controllingthesarscov2spikeglycoproteinconformation
AT koppmegan controllingthesarscov2spikeglycoproteinconformation
AT lidapeng controllingthesarscov2spikeglycoproteinconformation
AT parksrob controllingthesarscov2spikeglycoproteinconformation
AT hsuallenl controllingthesarscov2spikeglycoproteinconformation
AT borgniamarioj controllingthesarscov2spikeglycoproteinconformation
AT haynesbartonf controllingthesarscov2spikeglycoproteinconformation
AT acharyapriyamvada controllingthesarscov2spikeglycoproteinconformation